Acute High-intensity Interval Exercise Reduces Human Monocyte Toll-like Receptor 2 Expression in Type 2 Diabetes
Overview
Affiliations
Type 2 diabetes (T2D) is characterized by chronic low-grade inflammation that contributes to disease pathophysiology. Exercise has anti-inflammatory effects, but the impact of high-intensity interval training (HIIT) is not known. The purpose of this study was to determine the impact of a single session of HIIT on cellular, molecular, and circulating markers of inflammation in individuals with T2D. Participants with T2D ( = 10) and healthy age-matched controls (HC; = 9) completed an acute bout of HIIT (7 × 1 min at ~85% maximal aerobic power output, separated by 1 min of recovery) on a cycle ergometer with blood samples obtained before (Pre), immediately after (Post), and at 1 h of recovery (1-h Post). Inflammatory markers on leukocytes were measured by flow cytometry, and TNF-α was assessed in both LPS-stimulated whole blood cultures and plasma. A single session of HIIT had an overall anti-inflammatory effect, as evidenced by ) significantly lower levels of Toll-like receptor (TLR) 2 surface protein expression on both classical and CD16+ monocytes assessed at Post and 1-h Post compared with Pre ( < 0.05 for all); ) significantly lower LPS-stimulated TNF-α release in whole blood cultures at 1-h Post ( < 0.05 vs. Pre); and ) significantly lower levels of plasma TNF-α at 1-h Post ( < 0.05 vs. Pre). There were no differences between T2D and HC, except for a larger decrease in plasma TNF-α in HC vs. T2D (group × time interaction, < 0.05). One session of low-volume HIIT has immunomodulatory effects and provides potential anti-inflammatory benefits to people with, and without, T2D.
Orsatti F, de Queiroz Freitas A, Borges A, Santato A, DE Oliveira Assumpcao C, Souza M Mol Cell Biochem. 2024; 480(3):1381-1401.
PMID: 39172352 DOI: 10.1007/s11010-024-05089-8.
Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions.
Zhao L, Hu H, Zhang L, Liu Z, Huang Y, Liu Q MedComm (2020). 2024; 5(4):e516.
PMID: 38617433 PMC: 11014467. DOI: 10.1002/mco2.516.
Machrina Y, Anggraini D, Pane Y, Sari Harahap N, Pant G Med Arch. 2023; 77(4):276-280.
PMID: 37876569 PMC: 10591241. DOI: 10.5455/medarh.2023.77.276-280.
Maaloul R, Ben Dhia I, Marzougui H, Turki M, Hadj Kacem F, Makhlouf R Biol Sport. 2023; 40(4):1159-1167.
PMID: 37867744 PMC: 10588567. DOI: 10.5114/biolsport.2023.123323.
Macedo A, Schaan C, Bock P, Pinto M, Botton C, Umpierre D Arch Endocrinol Metab. 2023; 67(5):e230040.
PMID: 37738467 PMC: 10665050. DOI: 10.20945/2359-4292-2023-0040.